8 presentations were found matching your search word IS-S1 .

International Session (Symposium)1 (JSH, JSGE, JSGCS)

November 4, 9:30–12:00, Room 4 (Portopia Hotel South Wing Portopia Hall)

Lifestyle-related liver diseases: Elucidation of molecular mechanisms and development of new treatments

Allotted time: 15 min, for oral presentation, 3 min. for Q&A
Discussion: Not to be held
Introductory Meeting: Not to be held
  • Chairperson:
    Kazuhiko KoikeKanto Central Hospital
  • Chairperson:
    Takahiro KodamaDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
  • Discussant:
    Jacob GeorgeWestmead Hospital, University of Sydney
  • Discussant:
    Akiko EguchiDepartment of Gastroenterology and Hepatology, Mie University Graduate School of Medicine

IS-S1-1_H
Hydroxynonenal causes hepatocyte death by lysosomal disintegrity in NAFLD.

Takuya Seike Department of Gastroenterology, Kanazawa University

IS-S1-2_H
Thrombospondin-2 is a novel biomarker for advanced fibrosis and potential therapeutic target in nonalcoholic fatty liver disease

Kazuhiro Kozumi Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine

IS-S1-3_H
p62/SQSTM1 in hepatocytes plays a protective role against the development of steatohepatitis in mice

Kosuke Okada Faculty of Medicine, University of Tsukuba

IS-S1-4_H
Modulation of serotonin in the gut–liver neural axis ameliorates the progression of nonalcoholic fatty liver

Kenya Kamimura Department of General Medicine, Niigata University School of Medicine,Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University

IS-S1-5_H
Hepatocyte apoptosis links to decreased TET1 and 5-hydroxymethylcytosine formation: Possible role of α-Ketoglutarate in alcoholic and non-alcoholic fatty liver diseases

Katsuya Nagaoka Gastroenterology and Hepatology, Kumamoto University Hospital

IS-S1-6_H
Discovery of a novel therapeutic agent for NAFLD derived from VDR-silent vitamin D derivatives

Hayato Nakagawa Department of Gastroenterology, The University of Tokyo

IS-S1-7_G
Effects of SGLT2 Inhibitor on the Progression and Metabolisms in Metabolism-Associated Liver Cancer: Multi-Omics Analysis of Metabolomics/Proteomics

Takumi Kawaguchi Div. Gastroenterology, Dept. Medicine, Kurume University School of Medicine

IS-S1-8_H
NRF2 activator as dietary phytochemical against alcoholic liver disease-related fibrosis

Kosuke Kaji Department of Gastroenterology, Nara Medical University

Page Top

Page Top